Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic hepatitis B (CHB) treatment is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively.
DESIGN: This was a retrospective cohort study consisting of 231 and 560 patients enrolled in two phase IV, multicentre, randomised, controlled trials treated with Peg-IFN or NUC-based therapy for up to 2 years, respectively. Quantitative anti-HBc evaluation was conducted for all the available samples in the two trials by using a newly developed double-sandwich anti-HBc immunoassay.
RESULTS: At the end of trials, 99 (42.9%) and 137 (24.5%) patients achieved HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. We defined 4.4 log10 IU/mL, with a maximum sum of sensitivity and specificity, as the optimal cut-off value of baseline anti-HBc level to predict HBeAg seroconversion for both Peg-IFN and NUC. Patients with baseline anti-HBc ≥4.4 log10 IU/mL and baseline HBV DNA <9 log10 copies/mL had 65.8% (50/76) and 37.1% (52/140) rates of HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. In pooled analysis, other than treatment strategy, the baseline anti-HBc level was the best independent predictor for HBeAg seroconversion (OR 2.178; 95% CI 1.577 to 3.009; p<0.001).
CONCLUSIONS: Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Gut - 65(2016), 2 vom: 01. Feb., Seite 313-20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fan, Rong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.05.2016 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/gutjnl-2014-308546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM245315772 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM245315772 | ||
| 003 | DE-627 | ||
| 005 | 20240327231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/gutjnl-2014-308546 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1350.xml |
| 035 | |a (DE-627)NLM245315772 | ||
| 035 | |a (NLM)25586058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fan, Rong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2016 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ | ||
| 520 | |a OBJECTIVE: The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic hepatitis B (CHB) treatment is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively | ||
| 520 | |a DESIGN: This was a retrospective cohort study consisting of 231 and 560 patients enrolled in two phase IV, multicentre, randomised, controlled trials treated with Peg-IFN or NUC-based therapy for up to 2 years, respectively. Quantitative anti-HBc evaluation was conducted for all the available samples in the two trials by using a newly developed double-sandwich anti-HBc immunoassay | ||
| 520 | |a RESULTS: At the end of trials, 99 (42.9%) and 137 (24.5%) patients achieved HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. We defined 4.4 log10 IU/mL, with a maximum sum of sensitivity and specificity, as the optimal cut-off value of baseline anti-HBc level to predict HBeAg seroconversion for both Peg-IFN and NUC. Patients with baseline anti-HBc ≥4.4 log10 IU/mL and baseline HBV DNA <9 log10 copies/mL had 65.8% (50/76) and 37.1% (52/140) rates of HBeAg seroconversion in the Peg-IFN and NUC cohorts, respectively. In pooled analysis, other than treatment strategy, the baseline anti-HBc level was the best independent predictor for HBeAg seroconversion (OR 2.178; 95% CI 1.577 to 3.009; p<0.001) | ||
| 520 | |a CONCLUSIONS: Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB | ||
| 650 | 4 | |a Clinical Trial, Phase IV | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CORE ANTIBODY | |
| 650 | 4 | |a HEPATITIS B | |
| 650 | 7 | |a Hepatitis B Antibodies |2 NLM | |
| 650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Nucleosides |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Sun, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Xuefan |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Junqi |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Guangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Deming |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Mobin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shijun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinyue |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Jifang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Fengmin |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Jidong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Ningshao |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Jinlin |e verfasserin |4 aut | |
| 700 | 0 | |a Chronic Hepatitis B Study Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Xiaoguang |e investigator |4 oth | |
| 700 | 1 | |a Shi, Junping |e investigator |4 oth | |
| 700 | 1 | |a Ren, Hong |e investigator |4 oth | |
| 700 | 1 | |a Wang, Maorong |e investigator |4 oth | |
| 700 | 1 | |a Ma, Hong |e investigator |4 oth | |
| 700 | 1 | |a Gao, Zhiliang |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hongfei |e investigator |4 oth | |
| 700 | 1 | |a Chen, Chengwei |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Gut |d 1960 |g 65(2016), 2 vom: 01. Feb., Seite 313-20 |w (DE-627)NLM000003557 |x 1468-3288 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2016 |g number:2 |g day:01 |g month:02 |g pages:313-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/gutjnl-2014-308546 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2016 |e 2 |b 01 |c 02 |h 313-20 | ||